Cash, cash equivalents and financial assets of the Company amounted to €215.2 million i $79.1 million (€71.4 million ii ) in gross proceeds from our IPO on the Nasdaq and Global Offering Monalizumab to advance to Phase III clinical trial in combination with cetuximab in IO-pretreated SCCHN patients

Long-term data analysis will expand on previously reported efficacy results from Lumoxiti Phase III trial Marseille, France, November 7, 2019, 7:00 AM CET Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will share new, long-term data from

Preclinical data showcases advancement of its immuno-oncology portfolio across the Company’s three strategic pillars: immune checkpoint inhibitors, tumor antigen targeting and tumor micro-environment Marseille, France, November 6, 2019, 7:00 AM CET Innate Pharma SA (the “Company” - Euronext Paris: